Ovarian function after gonadotropin-releasing hormone agonist during chemotherapy in young breast cancer patients

Maturitas ◽  
2017 ◽  
Vol 100 ◽  
pp. 172-173 ◽  
Author(s):  
Dong-Yun Lee ◽  
Doo Seok Choi
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Ovarian Function ◽  
Gonadotropin Releasing Hormone ◽  
Breast Cancer Patients ◽  
Releasing Hormone ◽  
Gonadotropin Releasing Hormone Agonist ◽  
Young Breast Cancer

scholarly journals Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review

2019 ◽  
Vol 13 ◽  
pp. 117955811986458 ◽  
Author(s):  
Francesca Poggio ◽  
Matteo Lambertini ◽  
Claudia Bighin ◽  
Benedetta Conte ◽  
Eva Blondeaux ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Ovarian Function ◽  
Gonadotropin Releasing Hormone ◽  
Premature Menopause ◽  
Breast Cancer Patients ◽  
Premenopausal Breast Cancer ◽  
Releasing Hormone ◽  
Gonadotropin Releasing Hormone Agonist ◽  
Ovarian Protection

The use of chemotherapy in premenopausal cancer patients may lead to chemotherapy-induced premature ovarian failure. Pharmacological temporary ovarian suppression obtained with the gonadotropin-releasing hormone agonist (GnRHa) administered concomitantly with chemotherapy has been investigated as a technique capable to reduce the gonadotoxicity, reducing the risk of developing premature menopause. In recent years, important evidence has become available on the efficacy and safety of this strategy that should now be considered a standard option for ovarian function preservation in premenopausal breast cancer patients. However, in women interested in fertility preservation, this is not an alternative to cryopreservation strategies, which remains the first option to be proposed. The purpose of this review is to summarize the mechanisms of GnRHa in the preservation of fertility in premenopausal cancer patient candidates to receive chemotherapy, highlighting the areas of doubt that require further investigation.

scholarly journals Ovarian Function and Fertility Preservation in Breast Cancer: Should Gonadotropin-Releasing Hormone Agonist be administered to All Premenopausal Patients Receiving Chemotherapy?

2019 ◽  
Vol 13 ◽  
pp. 117955811982839 ◽  
Author(s):  
Matteo Lambertini ◽  
François Richard ◽  
Bastien Nguyen ◽  
Giulia Viglietti ◽  
Cynthia Villarreal-Garza
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Fertility Preservation ◽  
Clinical Evidence ◽  
Ovarian Function ◽  
Gonadotropin Releasing Hormone ◽  
Breast Cancer Patients ◽  
Premenopausal Breast Cancer ◽  
Ovarian Suppression ◽  
Gonadotropin Releasing Hormone Agonist

Chemotherapy-induced premature ovarian insufficiency (POI) is one of the potential drawbacks of chemotherapy use of particular concern for newly diagnosed premenopausal breast cancer patients. Temporary ovarian suppression obtained pharmacologically with the administration of a gonadotropin-releasing hormone agonist (GnRHa) during chemotherapy has been specifically developed as a method to counteract chemotherapy-induced gonadotoxicity with the main goal of diminishing the risk of POI. In recent years, important clinical evidence has become available on the efficacy and safety of this strategy that should now be considered a standard option for ovarian function preservation in premenopausal breast cancer patients, including women who are not interested in conceiving after treatment or that would not be candidates for fertility preservation strategies because of their age. Nevertheless, in women interested in fertility preservation, this is not an alternative to gamete cryopreservation, which remains as the first option to be offered. In this setting, temporary ovarian suppression with GnRHa during chemotherapy should be also proposed following gamete cryopreservation or to women who have no access, refuse, or have contraindications to surgical fertility preservation techniques. In this article, we present an overview about the role of temporary ovarian suppression with GnRHa during chemotherapy in breast cancer patients by addressing the available clinical evidence with the aim of identifying both the best candidates for the use of this strategy and the still existing gray zones requiring further investigation.

Sign in / Sign up

Export Citation Format

Share Document